ARCL Organics

Which are the latest news on ARCL Organics?

Why is ARCL Organics Ltd falling/rising?

As of 05-Sep, ARCL Organics Ltd's stock price is at 217.25, down 0.73%, with a year-to-date decline of 42.68%, significantly underperforming the Sensex. The stock's erratic trading and recent performance indicate a bearish trend and investor uncertainty.

As of 05-Sep, ARCL Organics Ltd's stock price is currently at 217.25, reflecting a decrease of 1.6, or 0.73%. The stock has shown a significant decline over various periods, with a year-to-date drop of 42.68% compared to a 10.21% decline in the Sensex, indicating that the stock has underperformed the broader market considerably. Over the past week, the stock has fallen by 6.36%, while the Sensex has only decreased by 0.97%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 1.15%. Additionally, the stock has experienced erratic trading, not trading on one day out of the last 20 days, which may contribute to investor uncertainty. Although there has been a slight increase in delivery volume by 14.98% against the 5-day average, the overall trading has been characterized by a narrow range of Rs 1.2, suggesting limited price movement.<BR><BR>Furthermore, while the stock is trading higher than its 50-day and 100-day moving averages, it is lower than its 5-day, 20-day, and 200-day moving averages, which may indicate a bearish trend in the short to medium term. Overall, the combination of significant year-to-date losses, underperformance relative to the sector, and erratic trading patterns contribute to the current decline in ARCL Organics Ltd's stock price.

Who are in the management team of ARCL Organics?

The management team of ARCL Organics includes Suraj Ratan Mundhra (Chairman), Ajay Kumar Minani (Whole-time Director), and Directors Trinetra Gokarannath Bajpai, Mukesh Mundhra, and Mihir Kumar Ghosh, who oversee the company's strategic direction and operations.

The management team of ARCL Organics includes the following individuals:<BR><BR>1. **Suraj Ratan Mundhra** - Chairman<BR>2. **Ajay Kumar Minani** - Whole-time Director<BR>3. **Trinetra Gokarannath Bajpai** - Director<BR>4. **Mukesh Mundhra** - Director<BR>5. **Mihir Kumar Ghosh** - Director<BR><BR>These individuals play key roles in guiding the company's strategic direction and operations.

What does ARCL Organics do?

ARCL Organics Ltd, a micro-cap company established in 1992, operates in the commodity chemicals industry and reported net sales of 67 Cr and a net profit of 9 Cr for June 2026. Key metrics include a P/E of 17.00 and a market cap of INR 194 Cr.

Overview: <BR>ARCL Organics Ltd operates in the commodity chemicals industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was established in 1992 and was initially known as Allied Chemical Private Limited. It changed its name to ARCL Organics Private Limited on January 11, 2010, and subsequently became a Public Limited Company on February 08, 2010. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 67 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 9 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 194 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Industry P/E: 22 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 6.98% <BR>Price to Book: 2.26 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the ARCL Organics?

ARCL Organics' peers include Andhra Petrochem, Genus Prime, and Kanchi Karpooram, among others. In terms of management risk, ARCL and Kanchi have excellent ratings, while Genus Prime shows good growth; ARCL's 1-year return is -17.75%.

Peers: The peers of ARCL Organics are Andhra Petrochem, Genus Prime, Hind.Organ.Chem., IVP, ZR2 Bioenergy, Kanchi Karpooram, Kesar Petroprod., Archit Organosys, and AG Ventures.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kanchi Karpooram and ARCL Organics, while Average management risk is found at Andhra Petrochem and IVP. Below Average management risk is present at Genus Prime, Hind.Organ.Chem., ZR2 Bioenergy, Kesar Petroprod., Archit Organosys, and AG Ventures, and the rest. Good growth is seen at Genus Prime, ARCL Organics, and Kesar Petroprod., while Below Average growth is noted at Andhra Petrochem, Hind.Organ.Chem., IVP, ZR2 Bioenergy, Kanchi Karpooram, Archit Organosys, AG Ventures, and the rest. Capital Structure is Excellent at Kanchi Karpooram and AG Ventures, Good at Andhra Petrochem, ARCL Organics, and Average at Archit Organosys, while Below Average is noted for Genus Prime, Hind.Organ.Chem., IVP, ZR2 Bioenergy, and Kesar Petroprod.<BR><BR>Return Snapshot: Genus Prime has the highest 1-year return at 72.28%, while ZR2 Bioenergy has the lowest at -70.89%. ARCL Organics' 1-year return of -17.75% is better than ZR2 Bioenergy's but worse than Genus Prime's. Additionally, Kesar Petroprod. and ZR2 Bioenergy have negative six-month returns.

How big is ARCL Organics?

As of 31st August, ARCL Organics Ltd has a market capitalization of 194.00 Cr, with recent Net Sales of 271.92 Cr and a Net Profit of 10.32 Cr.

As of 31st August, ARCL Organics Ltd has a market capitalization of 194.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, ARCL Organics reported Net Sales of 271.92 Cr and a Net Profit of 10.32 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 77.45 Cr and Total Assets of 168.89 Cr.

Should I buy, sell or hold ARCL Organics Ltd?

When is the next results date for ARCL Organics Ltd?

The next results date for ARCL Organics Ltd is 12 August 2026.

The next results date for ARCL Organics Ltd is scheduled for 12 August 2026.

Are ARCL Organics Ltd latest results good or bad?

ARCL Organics Ltd's latest results are concerning, showing a 50.18% decline in net profit year-on-year and a 9.59% drop in revenue, despite a sequential revenue improvement. With rising interest costs and a proprietary advisory score of 26 out of 100, the company is categorized as a "STRONG SELL," reflecting significant investor skepticism.

The latest results for ARCL Organics Ltd indicate a challenging financial situation. In Q4 FY26, the company reported a net profit of ₹2.79 crores, which represents a significant decline of 50.18% year-on-year. Revenue also fell by 9.59% compared to the same quarter last year, totaling ₹65.31 crores, although it did show a sequential improvement of 22.14% from the previous quarter.<BR><BR>Operating margins have improved to 10.84% from a negative margin in the prior quarter, but this is still below the 12.38% margin achieved in Q4 FY25. Additionally, the company is facing rising interest costs, with expenses climbing to ₹1.75 crores, the highest on record, which poses further pressure on profitability.<BR><BR>Overall, the financial performance reflects a mix of short-term recovery but significant year-on-year declines, leading to a proprietary advisory score of 26 out of 100, categorizing it in the "STRONG SELL" territory. The stock has also underperformed significantly, down 44.38% year-to-date, indicating a lack of investor confidence amidst these financial challenges.

How has been the historical performance of ARCL Organics?

ARCL Organics has experienced significant growth over the past four years, with net sales increasing from 141.26 Cr in Mar'22 to 250.59 Cr in Mar'25, and profit after tax rising to 12.33 Cr. Despite a slight decline in operating profit margin, the company has improved its earnings per share and total assets, indicating strong financial health.

Answer:<BR>The historical performance of ARCL Organics shows a steady growth in net sales and profitability over the past four years, with net sales increasing from 141.26 Cr in Mar'22 to 250.59 Cr in Mar'25. The total operating income has followed a similar upward trend, reaching 250.59 Cr in Mar'25, up from 141.26 Cr in Mar'22. The company's total expenditure has also risen, from 126.02 Cr in Mar'22 to 226.78 Cr in Mar'25, primarily driven by increased raw material costs, which rose from 107.66 Cr to 178.83 Cr during the same period. Operating profit (PBDIT) has improved from 17.63 Cr in Mar'22 to 26.16 Cr in Mar'25, although the operating profit margin has slightly declined from 10.79% to 9.5%. Profit before tax has shown a consistent increase, reaching 16.75 Cr in Mar'25, while profit after tax has also grown to 12.33 Cr from 10.53 Cr in Mar'22. The earnings per share have increased from 13.16 in Mar'22 to 15.41 in Mar'25, reflecting the company's profitability growth. On the balance sheet, total assets have increased from 97.89 Cr in Mar'22 to 168.89 Cr in Mar'25, with total liabilities also rising from 97.89 Cr to 168.89 Cr. The book value per share has improved significantly from 53.18 in Mar'22 to 96.81 in Mar'25. Cash flow from operating activities has shown variability, with a cash flow of 5.00 Cr in Mar'25 compared to 1.00 Cr in Mar'22.<BR><BR>Breakdown:<BR>ARCL Organics has demonstrated significant growth in its financial performance over the past four years. Net sales surged from 141.26 Cr in Mar'22 to 250.59 Cr in Mar'25, while total operating income mirrored this growth, reaching 250.59 Cr. Despite rising total expenditure, which increased to 226.78 Cr in Mar'25, the company managed to enhance its operating profit to 26.16 Cr, although the operating profit margin slightly decreased to 9.5%. Profit before tax rose to 16.75 Cr, and profit after tax reached 12.33 Cr, indicating a solid profitability trend. The earnings per share also improved, reflecting the company's financial health. On the balance sheet, total assets and liabilities both increased to 168.89 Cr, and the book value per share rose significantly, showcasing enhanced shareholder value. Cash flow from operating activities was 5.00 Cr in Mar'25, indicating a positive cash generation despite fluctuations in working capital. Overall, ARCL Organics has shown a robust growth trajectory in both revenue and profitability metrics.

Who are the top shareholders of the ARCL Organics?

The top shareholders of ARCL Organics are Arc Holdings Ltd with 15.29%, followed by Arcl Organics Ltd (SBICAP Trustee) at 11.28%, and individual investors holding 12.36%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of ARCL Organics include Arc Holdings Ltd, which holds the highest promoter stake at 15.29%. Additionally, the highest public shareholder is Arcl Organics Ltd, operated by SBICAP Trustee, with a holding of 11.28%. Individual investors collectively hold 12.36% of the company's shares. Notably, there are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company.

Is ARCL Organics overvalued or undervalued?

As of July 18, 2024, ARCL Organics is fairly valued with a PE ratio of 16.53 and an EV to EBITDA of 9.24, but despite a strong 1Y return of 361.31%, it does not qualify as a compelling investment compared to peers.

As of 18 July 2024, the valuation grade for ARCL Organics has moved from risky to does not qualify, indicating a significant change in its investment profile. The company appears to be fairly valued, with a PE ratio of 16.53, an EV to EBITDA of 9.24, and a ROCE of 19.92%. In comparison to peers, Chambal Fertilisers & Chemicals Ltd. has a more attractive PE ratio of 13.11, while Coromandel International Ltd. is deemed very expensive with a PE of 37.58.<BR><BR>Despite the recent stock performance showing a 1Y return of 361.31% compared to the Sensex's 7.53%, the current valuation metrics suggest that ARCL Organics is not undervalued. The company's ratios indicate it is positioned reasonably within its sector, but it does not present a compelling case for investment at this time.

What is the technical trend for ARCL Organics?

As of June 2, 2025, ARCL Organics shows a mildly bullish trend, supported by a bullish MACD and daily moving averages, but tempered by a mildly bearish KST and Dow Theory signals.

As of 2 June 2025, the technical trend for ARCL Organics has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the daily moving averages are also bullish, indicating some positive momentum. However, the weekly KST is mildly bearish and Dow Theory suggests a mildly bearish stance on the weekly timeframe. The Bollinger Bands on the monthly chart are mildly bullish, which provides some support to the overall mildly bullish outlook. The RSI shows no signals on both weekly and monthly timeframes, indicating a lack of momentum confirmation. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and daily moving averages, tempered by the mildly bearish KST and Dow Theory signals.

Has ARCL Organics declared dividend?

No Dividend History Available